Tonix Pharmaceuticals Holding Corp.
TNXP
$37.96
$2.115.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 2.43M | 2.58M | 2.82M | 2.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 2.43M | 2.58M | 2.82M | 2.21M |
| Cost of Revenue | 3.27M | 943.00K | 1.18M | 1.56M | 3.37M |
| Gross Profit | -1.27M | 1.49M | 1.40M | 1.27M | -1.16M |
| SG&A Expenses | 16.20M | 10.10M | 15.58M | 7.71M | 7.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.29M | 18.48M | 25.06M | 18.38M | 20.57M |
| Operating Income | -28.30M | -16.05M | -22.48M | -15.55M | -18.36M |
| Income Before Tax | -28.27M | -16.83M | -22.11M | -14.21M | -78.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.27M | -16.83M | -22.11M | -14.21M | -78.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.27M | -16.83M | -22.11M | -14.21M | -78.78M |
| EBIT | -28.30M | -16.05M | -22.48M | -15.55M | -18.36M |
| EBITDA | -28.06M | -15.56M | -21.51M | -15.04M | -16.95M |
| EPS Basic | -3.86 | -2.84 | -9.77 | -22.88 | -1.92K |
| Normalized Basic EPS | -2.41 | -1.55 | -6.10 | -14.30 | -302.04 |
| EPS Diluted | -3.86 | -2.84 | -9.77 | -22.88 | -1.92K |
| Normalized Diluted EPS | -2.41 | -1.55 | -6.10 | -14.30 | -302.04 |
| Average Basic Shares Outstanding | 7.33M | 5.93M | 2.26M | 621.20K | 41.00K |
| Average Diluted Shares Outstanding | 7.33M | 5.93M | 2.26M | 621.20K | 41.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |